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Background: We assessed the efficacy of serial interferon-gamma release assays (IGRAs) for the diagnosis of latent tuberculosis in-
fection (LTBI) in patients receiving immunosuppressive agents for treatment of rheumatic diseases in Korea.
Methods: Of 276 patients who underwent consecutive screening with one of two IGRAs [QuantiFERON-TB Gold or QuantiFERON-
TB Gold In-Tube], 66 patients were evaluated by the serial IGRA for detection of LTBI during therapy with immunosuppressive agents. 
Information on clinical diagnosis, medication, previous TB, blood cell count, tuberculin skin test, and interferon-gamma (IFN-γ) lev-
el measured by IGRA was collected.
Results: Of the 66 patients, the initial IGRA was positive in 24.2%, negative in 65.2%, and indeterminate in 10.6%. Forty-six patients 
(69.7%) showed consistent IGRA results during follow-up, and 13 patients (19.7%) had consistently positive results. IGRA conver-
sion rate was 12.1% (8/66) and reversion rate was 4.5% (3/66). Conversion of IGRA results was only observed in ankylosing spondy-
litis patients, and the median interval between the two tests in patients with conversion was 8.5 months. The mean IFN-γ level in 
the group of patients with consistently positive IGRA results was higher than that in the group with inconsistently positive results, 
although this trend was not statistically significant (P=0.293). Indeterminate results were observed most frequently in patients with 
systemic lupus erythematosus.
Conclusions: In patients receiving immunosuppressive agents, both IGRA conversions and reversions were observed. Serial IGRA 
testing may not be needed in patients with a positive initial IGRA result showing high IFN-γ levels, because of high consistency in 
the test results.
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INTRODUCTION
The vast majority of individuals who are exposed to My-
cobacterium tuberculosis do not develop active tuberculosis 
(TB) disease. Their immune systems are effective in contain-
ing the infection as a latent tuberculosis infection (LTBI). 
However, approximately 10% of individuals with LTBI will 
develop active TB disease. The risk of developing active TB 
disease increases in the presence of certain underlying me-
dical conditions (e.g., HIV infection, other types of immu-
nosuppression, and previous history of TB, as determined 
by chest X-ray) [1, 2]. Diagnosis of LTBI currently depends 
on tuberculin skin test (TST) reactivity. TST screening is 
recommended for contacts of TB patients and other groups 
who are at high risk of development of active TB disease. 
However, TST has some disadvantages, including the po-
tential for errors due to variability in methods of antigen 
application and subjective interpretation of results, and low 
specificity, as it cross-reacts with bacillus Calmette-Guérin 
(BCG) and nontuberculous environmental mycobacteria [3, 
4]. The TST-positive rate (induration diameter ≥10 mm) 
was 51% in a group of patients ranging in age from 24 to 36 
years, and up to 71% in a group having close contact with 272     www.kjlm.org
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TB patients in Korea, because BCG vaccination is manda-
tory in this country, causing high false positive rates [5]. A 
new test for LTBI, the interferon-gamma release assay (IG-
RA), has recently been developed, which measures inter-
feron-gamma (IFN-γ) release by T-cells stimulated in vitro 
with specific mycobacterial antigens. For the ELISA format, 
the QuantiFERON-TB Gold and QuantiFERON-TB Gold 
In-Tube tests (QFT-G and QFT-GIT; Cellestis Limited, Car-
negie, Victoria, Australia) are approved by the U.S. Food 
and Drug Administration (FDA). Another format, the en-
zyme-linked immunospot (ELISPOT) assay (T-SPOT.TB 
test; Oxford Immunotec Limited, Abingdon, United King-
dom) was approved by the FDA in 2008 [6]. Centers for 
Disease Control and Prevention (CDC) guidelines suggest 
that QFT-G can replace the TST under all circumstances in 
which the TST is currently used, including periodic testing 
[7]. Updated guidelines on the use of IGRAs were recently 
published, and it is recommended that an IGRA should be 
the preferred choice for testing persons who have received 
BCG as a vaccine. The use of IGRAs in this population is 
expected to improve diagnostic specificity and encourage 
acceptance of treatment of LTBI [8]. Investigation of LTBI 
in patients treated with immunosuppressive agents is im-
portant because such patients are at increased risk of LTBI 
reactivation [9]. For patients with rheumatic disease who 
have been treated with immunosuppressive agents for a long 
period of time, monitoring of LTBI is particularly necessary. 
However, serial IGRA testing of patients treated with im-
munosuppressive agents has rarely been studied.
In this study, we assessed the performance of IGRA in se-
rial testing for LTBI in rheumatic disease patients treated 
with immunosuppressive agents in Korea, an intermediate 
TB burden country. The levels of IFN-γ in patients with pos-
itive IGRA results were investigated and IGRA conversions 
and reversions were evaluated. 
MATERIALS AND METHODS
1. Study populations
From September 2006 to November 2010, 276 patients 
who were consecutively referred by the rheumatology de-
partment to the immunology laboratory of Dong-A Uni-
versity Hospital for an IGRA were initially enrolled in this 
study. Of these, 69 patients (25.0%) had serial IGRA results. 
A total of 210 specimens were obtained from these 69 pa-
tients. Patient charts were reviewed for demographic infor-
mation, clinical diagnosis, medication information, previ-
ous TB history, blood cell count, IFN-γ levels measured by 
the IGRA assay, and the results of TST. Rheumatic diagno-
ses were determined by specialist clinicians. Among these 
69 patients, 66 patients with rheumatic inflammatory dis-
ease who were treated with immunosuppressive agents were 
included in this study. Three patients, of whom two had fe-
ver of unknown origin and one had Kikuchi disease, were 
not treated with immunosuppressive agents, and therefore 
were excluded from the study. 
2. Interferon-gamma release assay 
A total of 66 patients who received immunosuppressive 
agents were serially screened using the QFT-G assay or QFT-
GIT assay. The QFT-G test (Cellestis Limited, Carnegie, Vic-
toria, Australia) was performed according to the manufac-
turer’s recommendations. Briefly, four aliquots of heparin-
ized whole blood were incubated with early secretory anti-
genic target-6 (ESAT-6), culture filtrate protein 10 (CFP-10), 
mitogen, and nil (i.e., saline) antigens. Following 12-18 hr 
of incubation at 37°C in a humidified atmosphere, the plasma 
was aspirated from each well, and the amount of IFN-γ was 
measured by ELISA. For an ELISA run to be valid, the fol-
lowing performance criteria had to be fulfilled: a variation 
coefficient <15% and a correlation coefficient of the stan-
dard curve >0.98. ELISA data were converted to IU/mL 
using the IFN-γ standard curve generated for each ELISA 
plate. IFN-γ values were calculated by subtracting the value 
obtained with nil antigens, with a cutoff value of 0.35 IU/mL 
according to the manufacturer’s instructions. The result of 
QFT-G was interpreted as indeterminate if the IFN-γ level 
was <0.35 IU/mL in the antigen stimulated wells and <0.5 
IU/mL in the mitogen well, when nil was ≤0.7 IU/mL. When 
nil was >0.7 IU/mL, the result was indeterminate when the 
IFN-γ level was <50% of nil in the antigen stimulated wells 
and there was any response in the mitogen well. In March 
2009, when the QFT-GIT assay was developed by the man-
ufacturer, we replaced QFT-G with QFT-GIT (Cellestis Li-
mited, Carnegie, Victoria, Australia). In QFT-GIT, the con-
trol material and antigens are contained in the same tubes 
as are used to collect blood for the test, thus allowing more 
direct testing of fresh blood. In addition, the TB 7.7 antigen 
was added to the combination of ESAT-6 and CFP-10 used 
in QFT-G. To measure the IFN-γ response to TB antigens, 
the IFN-γ concentration in plasma, from blood stimulated 
with a single cocktail of peptides representing ESAT-6, CFP-
10, and part of TB 7.7, was calculated minus nil. The QFT-
GIT test was also performed and interpreted according to 
the manufacturer’s recommendations. The IFN-γ response 
cutoff value was 0.35 IU/mL as in the QFT-G assay. Results 
with a nil of 0.7-8.0 IU/mL and an IFN-γ response of 25%-
50% of nil in QFT-GIT were interpreted as positive, whereas Kim K-H, et al.  •  Serial IGRAs for Latent TB Diagnosis
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in QFT-G these results were interpreted as indeterminate. 
Also, tests with a nil of 0.7-8.0 and an IFN-γ response of 
<25% of nil were interpreted as negative in QFT-GIT, wher-
eas in QFT-G they were interpreted as indeterminate. Con-
version of IGRA was defined as negative IGRA at baseline 
and positive IGRA at follow-up, and reversion of IGRA was 
defined as positive IGRA at baseline and negative IGRA at 
follow-up. 
3. Statistical analysis
Statistical analyses were conducted using MedCalc ver-
sion 9.3 (MedCalc Software, Mariakerke, Belgium). Con-
cordance between serial tests was assessed using kappa (κ) 
coefficients. The mean levels of IFN-γ in the different pa-
tient groups with initially positive IGRA results, and the 
differences in WBC, neutrophil, and lymphocyte counts 
between disease groups were compared by Kruskal-Wallis 
and Mann-Whitney tests. Fisher’s exact test was used to com-
pare the frequency of indeterminate results of IGRA accord-
ing to disease group. P values <0.05 were considered statis-
tically significant. 
RESULTS
1. Patients
Sixty-six patients who were treated with immunosup-
pressive agents were serially screened using the IGRA from 
September 2006 to November 2010. Table 1 shows the char-
acteristics of these patients. Twenty-one patients were treated 
with combined immunosuppressive agents. Tumor necrosis 
factor (TNF)-α antagonists were the most commonly used 
agents. All patients with ankylosing spondylitis (AS), six pa-
tients with rheumatoid arthritis (RA), a patient with Behçet’s 
disease, and a patient with juvenile rheumatoid arthritis re-
ceived TNF-α antagonists. Forty-seven patients (71.2%) were 
given their initial IGRA test prior to TNF-α antagonist ther-
apy, whereas 19 patients (28.9%) were initially examined by 
IGRA during their treatment with immunosuppressive agents. 
In addition, all patients were screened for active TB using 
chest X-rays and evaluation of clinical symptoms. Of 66 pa-
tients, five had a history of TB treatment, which is summa-
rized in Table 2. 
Thirty-three patients (50.0%) were treated for LTBI based 
on positive IGRA and/or TST results (Table 3). Twelve (36.4%) 
of the 33 patients were treated based on positive results of 
TST alone, two patients were retreated for LTBI because IG-
Table 1. Characteristics of the 66 rheumatic disease patients in this study 
treated with immunosuppressive agents and serially tested by IGRA
Characteristic
Age (mean±SD) (yr) 35.1±11.2
Male/Female 38/28
Diagnosis, N (%)
Ankylosing spondylitis 39 (59.1)
Systemic lupus erythematosus 11 (16.7)
Rheumatoid arthritis  10 (15.2)
Behçet’s disease 2 (3.0)
Adult-onset Still’s disease 2 (3.0)
Juvenile rheumatoid arthritis 1 (1.5)
Antiphospholipid syndrome 1 (1.5)
Immunosuppressive agents, N (%)
TNF-α antagonist   47 (71.2)
Methotrexate 16 (24.2)
Corticosteroid 16 (24.2)
Cyclosporin 5 (7.6)
Other  3 (4.5)
History of TB treatment, N (%) 5 (7.6)
Fibrotic changes on chest X-ray*, N (%) 3 (4.5)
LTBI treatment
†, N (%) 33 (50.0)
*Chest X-ray findings were consistent with previous tuberculosis disease; 
†Treatment 
of LTBI was performed based on a positive result from the interferon-gamma release 
assay and/or a positive response to the tuberculin skin test.
Abbreviations: SD, standard deviation; TNF, tumor necrosis factor; TB, tuberculosis; 
LTBI; latent tuberculosis infection.
Table 2. Summary of patients with history of TB treatment
Age Sex Diagnosis Result of serial IGRA TB disease
35 F SLE Consistently indeterminate Pulmonary TB at 32 years old
20 F SLE Reversion P ulmonary TB and TB colitis at 1st 
IGRA test
45 F RA Consistently positive Pulmonary TB at 22 years old 
39 M AS Consistently positive T B lymphadenitis 7 months prior 
to 1st IGRA test
33 M AS Consistently positive Pulmonary TB at 15 years old
Abbreviations: IGRA, interferon-gamma release assay; TB, tuberculosis; SLE, systemic 
lupus erythematosus; RA, rheumatoid arthritis; AS, ankylosing spondylitis.
Table 3. Treatment of latent tuberculosis infection according to distribution 
of IGRA results
IGRA result LTBI treatment+ LTBI treatment- Total (%)
Consistently negative 12* 17 29 (43.9)
Consistently positive 12   1 13 (19.7)
Consistently indeterminate   0   4 4 (6.1)
Changed result   9
† 11 20 (30.3)
Total 33 33 66
*Twelve patients were treated for LTBI based on the positive tuberculin skin test; 
†Eight 
patients with IGRA conversion and one patient with IGRA reversion were included.
Abbreviations: IGRA, interferon-gamma release assay; LTBI, latent tuberculosis infec-
tion.274     www.kjlm.org
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RA conversion was observed, and one patient was retreated 
due to an increased TST reaction. 
The mean time interval between IGRA tests was 9.2 mon-
ths (range 1-38), and the mean IGRA test number was 3.1 
(range 2-7). Thirty-one (47%) of the 66 patients received 
only two IGRA tests, and 16 patients (24.2%) received three 
tests. Two of the AS patients had six consecutive positive 
IGRA results and seven consecutive negative IGRA results, 
respectively. According to disease group, the mean number 
of IGRAs was 3.6 (range 2-7) for AS patients, 2.3 (range 2-3) 
for RA, 2.4 (range 2-4) for systemic lupus erythematosus 
(SLE), and 2.3 (range 2-3) for other diseases.
2.     Agreement between serial IGRAs and different types of 
IGRA 
A total of 203 IGRAs were performed. The initial IGRA 
result was positive in 16 patients (24.2%), negative in 43 
(65.2%), and indeterminate in seven (10.6%). Forty-six pa-
tients (69.7%) showed consistent IGRA results during fol-
low-up (Fig. 1). Agreement between results of the initial 
IGRA and those of the second IGRA was 69.7%, with a κ 
coefficient of 0.460 (95% confidence interval, 0.267-0.653). 
The percentage of consistent results from patients who had 
been tested with both QFT-G and QFT-GIT (26/37, 70.3%) 
was similar to that of patients tested with QFT-G only (12/16, 
75.0%) and that of patients tested with QFT-GIT only (8/13, 
61.5%) (Table 4). 
3. Conversion and reversion rates in serial IGRA
The IGRA conversion rate was 12.1% (8/66) and the re-
version rate was 4.5% (3/66). Conversion was only observed 
in AS patients (8/39, 20.5%). Among patients who received 
TNF-α antagonists, six of the eight non-AS patients showed 
consistently negative IGRA results. One patient of the re-
maining two had consistently positive IGRA results and the 
other patient had consistently indeterminate results. The 
median interval between two tests in patients with conver-
sion was 8.5 months (range 6-27). There were two patients 
Table 4. Number of patients according to the results and type of IGRA
IGRA result By QFT-G only  By QFT-GIT only  By both methods Total 
Consistently negative 8 (18) 4 (8) 17 (68) 29 (43.9%) (94)
Consistently positive 1 (2) 4 (8) 8 (29) 13 (19.7%) (39)
Consistently indeterminate 3 (7)                              0  1 (2) 4 (6.1%) (9) 
Changed result 4 (9) 5 (11) 11 (41) 20 (30.3%) (61)
Total (%) 16 (24.2%) (36, 17.7%)  13 (19.7%) (27, 13.3%) 37 (56.1%) (140, 70.0%) 66 (203)
Abbreviations: IGRA, interferon-gamma release assay; GFT-G, QuantiFERON-TB Gold test; QFT-GIT, QuantiFERON-TB Gold In-Tube test. Numbers in parentheses are numbers of speci-
mens.
Fig. 1. Study flow diagram. 
Abbreviations: IGRA, interferon-gamma release assay; AS, ankylosing spondylitis; RA, rheumatoid arthritis; SLE, systemic lupus erythematosus; JRA, juvenile rheu-
matoid arthritis; AOSD, adult-onset Still’s disease; I, indeterminate IGRA result.
66 patients receiving serial IGRA testing
IGRA
consistently negative
29 patients (43.9%)
94 specimens
IGRA
consistently positive
13 patients (19.7%)
40 specimens
IGRA
consistently indeterminate
4 patients (6.1%)
9 specimens
IGRA
changed results 
20 patients (30.3%)
60 specimens
AS  18
RA  6
SLE  2
Behcet disease  2
JRA  1
AS  11
RA  2
SLE  3
AOSD  1
Conversion  8 (12.1%)
Reversion  3 (4.5%)
I → Negative  3 (4.5%)
Negative → I  6 (8.7%)Kim K-H, et al.  •  Serial IGRAs for Latent TB Diagnosis
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who had showed consecutive conversion and reversion dur-
ing follow-up. One of the eight patients with conversion 
showed reversion after two consecutive positive results, and 
one of the three patients with reversion had a second posi-
tive result after three consecutive negative results. The mean 
level of IFN-γ response in the group with consistently posi-
tive IGRA results was higher than that in the groups with 
conversion or reversion, although the differences were not 
statistically significant (Tables 5 and 6). 
4.   Frequency of indeterminate results according to disease 
group
Overall, indeterminate IGRA results were observed in 
19/203 tests (9.4%). Of the 66 patients, 13 (19.7%) showed 
at least one indeterminate result, and four of these 13 pa-
tients had consistently indeterminate results. The percent-
age of indeterminate IGRA results differed significantly ac-
cording to disease group, and was highest among patients 
with SLE (8/11, 72.7%) (Table 7). The mean lymphocyte 
count of SLE patients (850/µL) was the lowest among the 
disease groups (P<0.001) (Table 8).
Table 5. Levels of interferon-gamma in patients with initial positive IGRA re-
sults
Group by IGRA results* (N) IFN-γ mean±SD (IU/mL)
Consistently positive (13) 4.9±6.8
†
Conversion (8) 1.8±1.8
Reversion (3) 1.0±0.3
*For the consistently positive and reversion groups, the initial IGRA result was used. 
For the conversion group, the first positive IGRA result was used. 
†P=0.293 by Krus-
kal-Wallis test.
Abbreviations: IGRA, interferon-gamma release assay; IFN-γ, interferon-gamma.
Table 6. Data on 20 patients with changed IGRA results
Age/Sex
IGRA* QFT-G: ESAT/CFP-10, QFT-GIT: TB response (IU/mL)
Interval (Mo) WBC (/µL) Dx TST
1st 2nd 3rd 4th 5th
Conversion
35/M N (-0.04/-0.04) P (0.6) P (0.8) - - 23/11 8,790/7,190/7,240 AS ND/+/+
31/M N (0.03/0.31) P (2.44) - - - 27 6,420/7,730 AS ND/+
28/M N (0.03) N (-0.01) P (0.66) - - 8/6 6,480/4,940/5,700 AS +/+/+
37/F N (0/0) N (0/0) N (-0.01/-0.03) N (0.03) P (1.57) 7/15/12/12 6,100/6,310/5,510/ND/ND AS ND/ND/ND/+/-
34/M N (-0.01) P (6.0) - - - 4 ND/10,020 AS ND
20/M N (0/0.08) N (0/0.01) N (-0.02/0.02) N (0.01) P (0.38) 6/18/9/7 7,610/5,890/6,310/7,500/7,460 AS -/-/ND/-/-
25/M N (-0.07/-0.1) P (1.0/-0.6) P (1.2/0.5) N (0.3) N (0.01) 7/15/3/12 6,780/6,770/ND/7,230/7,750 AS ND/ND/-/ND/-
37/M N (0.2/0.1) P (2.1) P (1.5) - - 6/16 8,780/8,700/7,040 AS +/-/ND
Reversion
25/M P (0.9/0.2) N (0.01/-0.18) N (0.2/-0.1) N (-0.9) P (0.7) 12/8/8/8 10,820/7,070/7,450/7,970/8,530 AS +/+/+/+/+
44/F P (1.4/0.4) N (0.02/0.01) - - - 5 6,000/5,230 RA +/ND
20/F P (0.9/0.3) N (0/0) - - - 7 2,560/5,480 SLE
†  ND
Indeterminate → negative
36/M I (-0.01/0) LM  N (0/0) N (-0.01) N (0,01) N (-0.04) 13/10/5/11 6,550/4,360/ND/4,400/5,000 AS ND/ND/-/-/-
54/F I (0.2/-0.04) LM I (-0.02/) LM N (0/0) - - 3/13 11,620/7,480/10,860 RA ND
39/F I (-0.01) LM N (-0.03) - - - 3 3,960/3,540 SLE ND
Negative → indeterminate
53/F N (0/0.02) I (-0.04) LM - - - 36 7,930/6,940 AOSD ND
43/F N (0) I (-0.01) LM - - - 2 10,510/1,230 SLE
‡ ND
24/F N (0.2) I (-0.05) LM - - - 1 9,680/21,230 APS ND
63/F N (0.03/0.02) I (0.01/-0.01) LM N (0.2) N (0.2) 2/12/4 12,950/11,260/14,030/8,090 SLE ND
20/F N (-0.01/0) N (0) I (0.01) LM - - 38/8 6,440/8,890/3,660 SLE ND
30/F N (0.01/-0.2) I (-0.1/-0.1) LM - - - 2 2,930/3,530 SLE ND
*Indicates the amount of IFN-γ in antigen stimulated wells (ESAT-6 and CFP-10 in QFT-G, TB response in QFT-GIT) subtracting the level in the nil well; 
†The patient was diagnosed 
with pulmonary TB and TB colitis; 
‡The patient had a fibrotic lesion on chest X-ray.
Abbreviations: IGRA, interferon-gamma release assay; GFT-G, QuantiFERON-TB Gold test; QFT-GIT, QuantiFERON-TB Gold In-Tube test; TST, tuberculin skin test; N, negative; P, posi-
tive; I, indeterminate; ND, not done; AS, ankylosing spondylitis; TB, tuberculosis; SLE, systemic lupus erythematosus; RA, rheumatoid arthritis; AOSD, adult-onset Still’s disease; APS, 
antiphospholipid syndrome; LM, low mitogen.276     www.kjlm.org
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DISCUSSION 
Investigation of LTBI in patients treated with immuno-
suppressive agents is important because such patients are at 
increased risk of LTBI reactivation [9]. Although it is com-
mon practice to screen patients for LTBI prior to commen-
cement of TNF-α antagonist therapy [10], guidelines for 
subsequent monitoring of LTBI in patients receiving immu-
nosuppressive agents, including TNF-α antagonists, have 
not been established. Monitoring of LTBI risk with IGRA 
has several advantages, including superior specificity com-
pared to TST, as demonstrated in the case of patients vacci-
nated with BCG, as well as avoidance of a second visit and 
subjective variability in TST results [11]. In our study, we 
assessed the performance of the IGRA in serial testing for 
LTBI in patients with rheumatic disease undergoing treat-
ment with immunosuppressive agents. Our study shows 
that the initial results of IGRA are in fair agreement with 
those of follow-up IGRA during immunosuppressive ther-
apy in a country with an intermediate TB burden. IGRA 
conversion was observed in eight patients (12.1%) who re-
ceived TNF-α antagonists, and was only observed in AS pa-
tients (20.5%). Among patients who received TNF-α antag-
onists, six of eight non-AS patients showed consistently ne-
gative IGRA results, and the remaining two patients had 
consistently positive results and consistently indeterminate 
results, respectively. The reason for the occurrence of IGRA 
conversion only in AS patients is uncertain, although a pre-
vious study reported that the TST conversion rate was sig-
nificantly higher in AS patients than in RA patients, when 
both groups received TNF-α antagonists [12]. In 27 RA pa-
tients in Taiwan who had completed a 12-month period of 
therapy with TNF-α antagonists, conversion of QFT-G was 
not observed [13]. In our study, the median interval between 
two tests in patients with conversion was 8.5 months, which 
is a relatively short period. Further studies are needed to es-
tablish the most appropriate follow-up interval for IGRA in 
patients treated with TNF-α antagonists. The conversion 
rate of IGRA may differ according to disease group and du-
ration of follow-up. Further studies would also clarify the 
factors affecting IGRA conversion.
Among patients with positive IGRA results, nearly 20% 
(13/66, 19.7%) had consistently positive results. The mean 
level of IFN-γ response in consistently IGRA-positive pa-
tients was higher than that in patients with IGRA reversion, 
indicating that results showing a low positive IFN-γ response 
tend to be inconsistent. Two (3.0%) of the 66 patients show  ed 
both conversion and reversion in our study. Similar results 
were reported from a study of the reproducibility of QFT-
GIT in a targeted US screening population. In that study, 
transient responses to QFT-GIT were common; therefore, it 
was concluded that low positive IFN-γ results (<0.69 IU/
mL) should be interpreted with caution [14]. In our study, a 
SLE patient who showed a low IFN-γ response for ESAT-6 
only was diagnosed as having active pulmonary TB and TB 
colitis, and the result of QFT-G was found to be negative 18 
months later. In a study by Chen et al. [13], two patients 
who showed reversion on the QFT-G test had clinical TB 
diseases, such as TB arthritis and TB pleurisy. The clinical 
significance of reversion may be different in cases of tran-
sient responses to contact infection, and in patients who 
have received immunosuppressive agents. Further study is 
needed to define the clinical significance of IGRA reversion.
Traditionally, TST was the only practical immunological 
test for the diagnosis of LTBI before the development of IG-
RA. In this study, 12 (36.4%) of the 33 patients who received 
treatment for LTBI were treated based on positive TST re-
sults only. A similar result was reported in a study from Ko-
rea. Of 28 converted TST-positive immune mediated in-
flammatory disease patients who had received TNF-α an-
tagonists, 16 patients were examined by IGRA, and only 
five results were positive [12]. These data indicate that posi-
Table 7. Frequency of indeterminate IGRA results according to disease group
Disease  
(N of patients)
Indeterminate,  
N (%)
Indeterminate  
result/total test, N (%)
AS (39) 1/39 (2.6) 1/140 (0.7) P<0.0001
SLE (11)  8/11 (72.7) 12/26 (46.2) P<0.0001
RA (10) 1/10 (10.0) 2/23 (8.7) P=0.998
Other diseases (6)   3/6 (50.0) 4/14 (28.6) P=0.03
Total (66) 13/66 (19.7) 19/203 (9.4)
The proportion of indeterminate results in total tests was compared with that of all 
patients by Fisher’s exact test. 
Abbreviations: IGRA, interferon-gamma release assay; AS, ankylosing spondylitis; SLE, 
systemic lupus erythematosus; RA, rheumatoid arthritis. 
Table 8. Relationship between blood cell parameters and disease group
Disease  
(N of pt/ N of test) WBC* (µL) Neutrophil
† (µL)  Lymphocyte
† (µL)
AS (39/115) 7,452±2,200
‡ 4,216±1,996
‡ 2,376±694
‡
SLE (11/26) 7,432±5,023
‡ 6,120±4,653 850±414
‡
RA (10/20) 8,955±3,192 6,405±3,125 1,847±753
‡
Other diseases (6/14) 11,722±5,078
‡ 9,032±4,429
‡ 1,579±710
Results are expressed as mean±SD. 
*P=0.003; 
†P=0.001 by Kruskal-Wallis test; 
‡P<0.001 by Mann-Whitney test. 
Abbreviations: pt, patient; AS, ankylosing spondylitis; SLE, systemic lupus erythema-
tosus; RA, rheumatoid arthritis. Kim K-H, et al.  •  Serial IGRAs for Latent TB Diagnosis
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tive TST is more prevalent than positive IGRA among pa-
tients who have received TNF-α antagonists in Korea. These 
discrepancies may be explained by a cross-reaction with non-
tuberculous mycobacteria in TST and false negative results 
of IGRA [15, 16]. Further study is needed to establish opti-
mal screening guidelines for LTBI in patients who have re-
ceived TNF-α antagonists in areas with mandatory BCG 
vaccination.
Four (6.1%) of 66 rheumatic disease patients who received 
immunosuppressive agents showed continuously indeter-
minate GFT-G results. Published data on the overall rate of 
indeterminate results from patients with rheumatic diseases 
are comparable to our results, ranging from 1.9% to 6% [17-
19]. In contrast, a high rate of indeterminate QFT-G test re-
sults (28.6%) was previously reported amongst RA patients 
[20]. Although patients with indeterminate results are re-
ported as having a statistically significant change in test re-
sults upon follow-up QFT-G (23%) [18], only three patients 
(4.5%) showed a change from indeterminate results in the 
present study. 
In our study, indeterminate results were observed most 
frequently in patients with systemic lupus erythematosus. 
Kobashi et al. reported that four of five active TB patients 
with indeterminate QFT-TB (corresponding to QFT-G) re-
sults had moderate lymphocytopenia [21]. In another re-
cent study, the sensitivity of IGRA partly depended on pe-
ripheral lymphocyte counts and under low lymphocyte co-
unt conditions, ELISPOT was superior to QFT-G for de-
tecting TB [22]. Lymphocytopenia is a frequent finding in 
SLE patients. In the present study, 8 of 11 SLE patients showed 
at least one indeterminate response during the follow-up 
period, and lymphocytopenia was observed only in SLE pa-
tients. Although the number of patients in our study is lim-
ited, these observations suggest that the results of IGRA may 
be influenced by cellular factors of the host. 
In conclusion, conversions and reversions were observed 
in patients receiving immunosuppressive agents. Serial IGRA 
testing may not be needed in patients with positive initial 
IGRA results showing high IFN-γ levels, because of the con-
sistency in the results of IGRA over a considerable period of 
time. The relationship between the magnitude of change in 
IFN-γ level, as measured by IGRA, and conversion and re-
version rates requires further clarification.
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